Revance Therapeutics reported $280M in Debt for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Debt Change
Adamas Pharmaceuticals ADMS:US 4.17M 125.57M
Aerie Pharmaceuticals AERI:US $ 222.02M 5.94M
ALKERMES ALKS:US $ 296.44M 0.63M
Antares Pharma ATRS:US $ 26.15M 14.87M
Bristol Myers Squibb BMY:US $ 44742M 416M
Cara Therapeutics CARA:US $ 0 0
Coherus Biosciences CHRS:US $ 406.09M 0.44M
Eli Lilly And LLY:US $ 17085.4M 570.3M
Endo International Ordinary Shares ENDP:US $ 8304.11M 3.58M
Flexion Therapeutics FLXN:US $ 221.55M 1.81M
Gw Pharmaceuticals GWPH:US $ 15.19M 0.11M
Horizon Pharma HZNP:US $ 2576.44M 2.07M
JAZZ PHA JAZZ:US $ 6744.3M 4642.65M
Merk MRK:US $ 26521M 4732M
Neurocrine Biosciences NBIX:US $ 326.3M 4.3M
Pacira Pharmaceuticals PCRX:US $ 475.39M 6.4M
Procter & Gamble PG:US $ 32547M 559M
Revance Therapeutics RVNC:US $ 280M 0.31M
Supernus Pharmaceuticals SUPN:US $ 370.38M 18.83M
Teva Pharmaceutical Industries TEVA:US $ 23746M 1386M
Zogenix ZGNX:US $ 153.63M 2.18M